CD8A and glioblastoma: In contrast, those GBM patients with high CD8+ T cell abundance and low CD69 expression (Figure 7B, group 2) exhibited reduced cumulative survival (approximately 20 months) compared to those patients with low CD8+ T cell abundance and low CD69 expression (Figure 7B, group 1), who showed >40 months survival.